Xavier, Catarina
Blykers, Anneleen
Laoui, Damya
Bolli, Evangelia
Vaneyken, Ilse
Bridoux, Jessica
Baudhuin, Henri
Raes, Geert
Everaert, Hendrik
Movahedi, Kiavash
Van Ginderachter, Jo A.
Devoogdt, Nick
Caveliers, Vicky
Lahoutte, Tony
Keyaerts, Marleen http://orcid.org/0000-0002-9997-4571
Funding for this research was provided by:
H2020 Marie Sk?odowska-Curie Actions (EU-H2020-MSCA-ITN-PET3D, EU-H2020-MSCA-ITN-PET3D)
Research Foundation-Flanders (Senior Clinical Investigator, Senior Clinical Investigator)
Nationaal KankrplanA (Actie 29)
?Kom op tegen Kanker? (multiple)
IWT (SBO Inflammatrack)
Scientific Fund W. Gepts UZ Brussel
Article History
First Online: 22 January 2019
Compliance with Ethical Standards
: All procedures followed the guidelines of the Belgian Council for Laboratory Animal Science and were approved by the Ethical Committee for Animal Experiments of the Vrije Universiteit Brussel (license 13-272-5).
: KM received travel and accommodation expenses from Bayer; KM and CV have received research funding from Camel-IDS. DN, LT, and RG are co-founders of and/or employed by Camel-IDS. DN has received funding from Boehringer-Ingelheim, Complix, Agenus, and Telix Pharma. KM, LT, DN, RG, VGJ, XC, and BJ have patents on nanobody imaging and therapy. LT received honoraria from Camel-IDS, IBA, and Institut des Radioéléments (IRE).